Tag Archives: gene therapy

By Deanna Petersen and Holly May, Chief Business Officer and Chief Commercial Officer, respectively, of AVROBIO, as part of the From The Trenches feature of LifeSciVC Moving from traditional drug development and commercialization to gene therapy development and commercialization can

By Deanna Petersen, chief business officer at AVROBIO, and Georgette Verdin, chief human resources officer at AVROBIO, as part of the From The Trenches feature of LifeSciVC. As we approach our 5th anniversary and surpass our 125th hire, we have

This blog post was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC. When AVROBIO went public in June 2018, I found myself on the steep end of an unexpected but interesting

This blog was written by Deanna Petersen, CBO of AVROBIO (@dmp9818), as part of the From The Trenches feature of LifeSciVC. Building a leading gene therapy pipeline in under two years (and a lot of air miles): how to persevere

This post was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. Today I will continue my time-honored January tradition of an optimistic blog post providing some bold predictions for the

Last week, AvroBio and Magenta Therapeutics priced their IPOs on the same night. Less than three months earlier, Unum Therapeutics priced its IPO. All three biotech companies are emerging leaders in the cell and gene therapy space, broadly defined. They

This blog was written by Deanna Petersen, Chief Business Officer of AvroBio, as part of the From The Trenches feature of LifeSciVC.   It seems so clear now: gene therapy is on a roll.  As 2017 came to a close, the

The field of gene and cell therapy has witnessed an unprecedented few months, almost unimaginable only a few years ago. It’s worth pausing to reflect on some of the recent highlights: FDA approval of two chimeric antigen receptor (CAR) T-cell

This post was written by Jason Gardner, Atlas EIR and CEO of Magenta Therapeutics, as part of the From The Trenches feature of LifeSciVC. A new type of medicine was approved in Europe at the end of May that culminated

The exciting renaissance in cell and gene therapy over the past five years has yielded some of the most innovative medical advances in the industry’s pipeline today.  There are now multiple stories of patients getting “cured” of rare diseases, responding